Korean bio-pharma companies attract attention at AACR 2021
By Whang, byung-woo | translator Alice Kang
21.04.13 09:05:43
가나다라
0
Domestic biopharma companies present potential of combination therapies and preclinical studies
AARC holds Annual Meeting on Novel Approaches to Enhance Immunotherapy … combination therapies receive attention
The AACR 2021 Annual Meeting, the largest meeting on cancer research in the world, took place from April 10th to April 15th. At the meeting, new combination therapies were introduced, raising expectations for the use of new mechanisms of action in the field of cancer treatment.
Through a presentation of data on the use of nivolumab (Opdivo) in early-stage non-small cell lung cancer (NSCLC), Bristol Myers Squibb (BMS) presented its next target area for its PD-1/L1 inhibitor. Bayer appealed the efficacy of its PI3K inhibitor copanlisib (Aliqopa) in combination with rituximab.
Results of Combination therapy studies show potential to expand treatment scope
The pr
Whang, byung-woo(news@medicaltimes.com)
If you want to see the full article, please JOIN US (click)